Braveheart Bio priced an upsized initial public offering on Nasdaq to take Hengrui’s cardio asset into Phase 3, marking the second time this year a U.S.-listed biotech emerged from Hengrui’s pipeline lineage. The company’s listing follows a period of heavy interest in crossover pipeline stories and platform-backed development strategies. Separately, multiple IPO updates continued to signal that immunology and inflammation specialists are leaning into public markets to fund late-stage expansion. Together, the financings underscore how quickly capital formation is reopening for companies with near-term clinical milestones. For investors, the key question becomes not access to capital but execution speed into Phase 3 and the ability to translate partnering-era assets into independently valued clinical readouts.